Teens With Opioid Use Disorder Are Being Denied Medication Detox

Adolescents struggling with opioid use disorder face the highest overdose risk of any age group, yet they remain the least likely to receive medication-assisted treatment.

A peer-reviewed study published in Cureus in May 2026 examined two decades of evidence and found that structural barriers, clinician hesitancy, and regulatory confusion are keeping a proven, life-saving treatment out of reach for young people who need it most.

Why Medical Detox and MAT Are Critical for Adolescents

When a teenager develops opioid use disorder (OUD), the stakes are immediate and severe. Fentanyl now dominates the illicit drug supply, meaning that any opioid use, even experimental or occasional, carries an extraordinary risk of fatal overdose.

For adolescents already dependent on opioids, the pathway to safety runs directly through medically supervised detox and medication-assisted treatment.

Research consistently shows that buprenorphine improves treatment retention, reduces opioid use, and decreases high-risk behaviors in adolescents, and it is well tolerated. Despite this, the treatment gap is staggering.

Only 5 to 10 Percent of Teens With OUD Receive Treatment

Real-world data indicate that only 5 to 10% of adolescents with opioid use disorder receive any medication for OUD (MOUD), even though this age group carries the highest overdose risk. That means the vast majority of teens who could benefit from medication-assisted treatment never receive it.

The Cureus review identified the core reasons for this gap, and notably, lack of evidence is not among them.

The persistent undertreatment of adolescents with OUD reflects structural barriers, clinician hesitancy, regulatory misconceptions and the absence of an FDA indication for this age group, not a lack of efficacy. In other words, the medicine works. The system is failing.

What Is Buprenorphine and How Does It Work in Detox

Buprenorphine is a partial opioid agonist, a medication that activates opioid receptors in the brain enough to prevent withdrawal symptoms and cravings, but with a “ceiling effect” that limits the risk of respiratory depression and overdose.

It is one of the cornerstones of medication-assisted treatment for opioid detox and long-term recovery, often combined with naloxone (sold as Suboxone) to deter misuse.

Comparative effectiveness studies show a lower overdose risk with buprenorphine than with methadone in adolescent populations, and recent fentanyl-era feasibility studies confirm that successful treatment induction is possible even among youth who have been using illicit fentanyl exclusively.

Longer treatment durations also produce markedly better outcomes. Across the research, longer treatment durations reliably outperform short tapers, a critical point for families who may worry that medication-assisted treatment simply trades one dependency for another. The evidence says otherwise: sustained treatment saves lives.

Every Major Medical Organization Endorses This Treatment

This is not a fringe position. All major medical organizations, including the American Society of Addiction Medicine, the American Academy of Pediatrics, the American Academy of Child and Adolescent Psychiatry, the Society for Adolescent Health and Medicine, the British Columbia Centre on Substance Use and the World Health Organization, endorse buprenorphine medication for adolescents with OUD.

The authors of the Cureus review concluded that withholding medication-assisted treatment from teens is not clinically justified.

With illicitly manufactured synthetic opioids now dominating the drug supply, denying buprenorphine to adolescents is not evidence-based, it reflects a longstanding pattern of excluding young people from treatments known to save lives.

What Families Should Know About Opioid Detox Programs

If your child or a teenager you love is struggling with opioid use, the most important step is connecting with a medically supervised detox program that offers evidence-based medication-assisted treatment.

Opioid withdrawal, while rarely fatal on its own, is intensely uncomfortable and frequently drives people back to use, which in the fentanyl era can be immediately deadly.

Detox programs that offer buprenorphine induction as part of a broader opioid use disorder treatment plan provide the safest bridge from active use to recovery. Look for programs with:

1. Medical staff trained in addiction medicine
2. Access to buprenorphine or other MOUD
3. A transition plan to ongoing outpatient MAT or residential care
4. Services appropriate for adolescents or young adults

The level of care needed depends on the severity of dependence. The American Society of Addiction Medicine (ASAM) defines Level 4 as medically managed intensive inpatient detox, the highest level of medical supervision, while Level 3.7 involves medically monitored inpatient treatment for those who need 24-hour clinical oversight without intensive care resources.

Finding Medical Detox for Opioid Use Disorder

If your family is seeking opioid detox options, don’t navigate this alone. Explore detox.com’s directory to find detox centers near you.

Call 800-996-6135(Sponsored) to speak with a treatment specialist about medically supervised detox programs in your area. Programs are available for adolescents and adults, and many accept insurance.